Jan 9, 2008 ApaTechTM announces the launch of ActifuseTM ABX 1.5ml
ApaTech, a world leader in bone graft technology, is pleased to announce the launch of ActifuseTM ABX in a specially designed 1.5ml narrow diameter applicator.
CEO Simon Cartmell said “Having witnessed the rapid adoption of Actifuse ABX, we are very pleased to introduce this smaller volume product for use in small defect filling, trauma applications and to fill small volume spinal cages. We are dedicated to making Actifuse ABX the bone grafting material of choice for surgeons. Ease of use applicators are a key part of this strategy and ApaTech plans a number of product launches through the coming 12 months.” Ready for immediate use, the 1.5ml applicator is ergonomically designed and dispense 100% Actifuse ABX. The indications for use for Actifuse ABX 1.5ml include posterolateral spine fusion with appropriate stabilizing hardware (PLF), in addition to general bone void filler applications. Actifuse ABX was the first synthetic graft material to be indicated by the FDA for this widely used technique.
Actifuse Advanced Bone matriX (ABX) provides surgeons with osteostimulative Actifuse granules as a moldable, cohesive mass in an easy to use applicator. As a result, surgeons can place Actifuse ABX directly into the operative site. Actifuse ABX provides surgeons with the handling benefits associated with demineralized bone matrix putties but in a product with a high volume of osteoconductive and osteostimulative scaffold.
Dr. Tushar Patel, Fairfax, Virginia stated: “We have had the opportunity, in our practice, to use and evaluate a significant number of bone graft substitutes and DBMs. Actifuse ABX represents a major step forward in the search for the ideal bone grafting material, combining the osteostimulative benefits of the Actifuse scaffold with the placement benefits and moldability of a putty. The handling properties and ease of use of Actifuse ABX are truly excellent.”
The unique, silicate substituted calcium phosphate chemistry of Actifuse is a significant advance in synthetic bone graft technology and provides surgeons with a safe and effective alternative to autograft, allograft, DBMs and BMPs. Actifuse enhances the formation of bone and improves the subsequent organization and strength of the graft/host bone composite structure. Unlike traditional calcium phosphate based products, Actifuse is steadily and predictably remodeled by the host biology over time, ensuring that sufficient conductive scaffold remains for the duration of new bone growth and its subsequent maturation. Distinct from allograft and demineralized bone matrix sourced from cadaveric bone, Actifuse ABX is synthetic and, as a result, free of pathogens. This means that there is consistency lot to lot, no risk of infection due to human or animal infective agent transmission from the graft material, and being synthetic, there have been no reports of adverse immunological reactions.
CEO Simon Cartmell said “Having witnessed the rapid adoption of Actifuse ABX, we are very pleased to introduce this smaller volume product for use in small defect filling, trauma applications and to fill small volume spinal cages. We are dedicated to making Actifuse ABX the bone grafting material of choice for surgeons. Ease of use applicators are a key part of this strategy and ApaTech plans a number of product launches through the coming 12 months.” Ready for immediate use, the 1.5ml applicator is ergonomically designed and dispense 100% Actifuse ABX. The indications for use for Actifuse ABX 1.5ml include posterolateral spine fusion with appropriate stabilizing hardware (PLF), in addition to general bone void filler applications. Actifuse ABX was the first synthetic graft material to be indicated by the FDA for this widely used technique.
Actifuse Advanced Bone matriX (ABX) provides surgeons with osteostimulative Actifuse granules as a moldable, cohesive mass in an easy to use applicator. As a result, surgeons can place Actifuse ABX directly into the operative site. Actifuse ABX provides surgeons with the handling benefits associated with demineralized bone matrix putties but in a product with a high volume of osteoconductive and osteostimulative scaffold.
Dr. Tushar Patel, Fairfax, Virginia stated: “We have had the opportunity, in our practice, to use and evaluate a significant number of bone graft substitutes and DBMs. Actifuse ABX represents a major step forward in the search for the ideal bone grafting material, combining the osteostimulative benefits of the Actifuse scaffold with the placement benefits and moldability of a putty. The handling properties and ease of use of Actifuse ABX are truly excellent.”
The unique, silicate substituted calcium phosphate chemistry of Actifuse is a significant advance in synthetic bone graft technology and provides surgeons with a safe and effective alternative to autograft, allograft, DBMs and BMPs. Actifuse enhances the formation of bone and improves the subsequent organization and strength of the graft/host bone composite structure. Unlike traditional calcium phosphate based products, Actifuse is steadily and predictably remodeled by the host biology over time, ensuring that sufficient conductive scaffold remains for the duration of new bone growth and its subsequent maturation. Distinct from allograft and demineralized bone matrix sourced from cadaveric bone, Actifuse ABX is synthetic and, as a result, free of pathogens. This means that there is consistency lot to lot, no risk of infection due to human or animal infective agent transmission from the graft material, and being synthetic, there have been no reports of adverse immunological reactions.
